UniD Manufacturing

UniD Manufacturing is a specialized CDMO offering integrated R&D and manufacturing services for polymer-based long-acting drug formulations. The company operates a GMP-approved facility in Liège, Belgium, and serves biotech and pharma partners with expertise in extrusion, co-extrusion, and injection molding for complex dosage forms like vaginal rings and ophthalmic implants. With a seasoned leadership team and backing from notable Belgian life science investors, UniD is positioned to capitalize on the growing demand for sustained-release technologies that improve patient adherence. Its business model is service-based, generating revenue through development and manufacturing contracts.

Three polymer technology platforms for sustained drug release: 1) Non-biodegradable polymers for long-term release (up to 9 years), 2) Biodegradable polymers for mid-term release (3-18 months), and 3) Resorbable polymers for short-term release (1 day to 3 months). Supported by extrusion, co-extrusion, and injection molding manufacturing techniques.

UniD competes in the niche segment of polymer-based drug delivery CDMOs against players like Evonik Health Care, Lubrizol Life Science, and other specialized firms. Its key differentiators are its exclusive focus on long-acting formulations, integrated end-to-end services from a single site in Europe, and over 20 years of collective team expertise in this specific domain.